Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies

Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies

B lymphocytes play a critical role in humoral immunity. Abnormal B cell development and function cause a variety of hematological malignancies such as myeloma, B cell lymphoma, and leukemia. Histone deacetylase 6 (HDAC6) inhibitors alone or in combination with other drugs have shown efficacy in seve...

Full description

Bibliographic Details
Main Authors: Jia Yang, Dengwen Li, Jun Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Pharmacology
Subjects:
B lymphocyte
hematological malignancy
multiple myeloma
B-cell non-Hodgkin lymphoma
histone deacetylase 6 (HDAC6)
inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00971/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00971/full

Similar Items